Immuneering (IMRX) Competitors $3.39 -0.20 (-5.57%) Closing price 07/3/2025 03:57 PM EasternExtended Trading$3.38 -0.02 (-0.44%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMRX vs. BCYC, MNMD, VALN, ZVRA, KURA, TYRA, BCAX, ABVX, SEPN, and ORGOShould you be buying Immuneering stock or one of its competitors? The main competitors of Immuneering include Bicycle Therapeutics (BCYC), Mind Medicine (MindMed) (MNMD), Valneva (VALN), Zevra Therapeutics (ZVRA), Kura Oncology (KURA), Tyra Biosciences (TYRA), Bicara Therapeutics (BCAX), Abivax (ABVX), Septerna (SEPN), and Organogenesis (ORGO). These companies are all part of the "pharmaceutical products" industry. Immuneering vs. Its Competitors Bicycle Therapeutics Mind Medicine (MindMed) Valneva Zevra Therapeutics Kura Oncology Tyra Biosciences Bicara Therapeutics Abivax Septerna Organogenesis Immuneering (NASDAQ:IMRX) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk. Which has more volatility & risk, IMRX or BCYC? Immuneering has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. Comparatively, Bicycle Therapeutics has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Which has preferable earnings & valuation, IMRX or BCYC? Immuneering has higher earnings, but lower revenue than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmuneering$320K381.27-$61.04M-$1.96-1.73Bicycle Therapeutics$35.28M14.57-$169.03M-$3.14-2.36 Is IMRX or BCYC more profitable? Immuneering has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -790.07%. Bicycle Therapeutics' return on equity of -25.54% beat Immuneering's return on equity.Company Net Margins Return on Equity Return on Assets ImmuneeringN/A -119.22% -99.22% Bicycle Therapeutics -790.07%-25.54%-21.23% Does the media refer more to IMRX or BCYC? In the previous week, Immuneering had 2 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 8 mentions for Immuneering and 6 mentions for Bicycle Therapeutics. Immuneering's average media sentiment score of 1.56 beat Bicycle Therapeutics' score of 0.32 indicating that Immuneering is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immuneering 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Bicycle Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders believe in IMRX or BCYC? 67.7% of Immuneering shares are owned by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are owned by institutional investors. 22.9% of Immuneering shares are owned by company insiders. Comparatively, 22.9% of Bicycle Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer IMRX or BCYC? Immuneering presently has a consensus price target of $13.25, indicating a potential upside of 290.86%. Bicycle Therapeutics has a consensus price target of $25.00, indicating a potential upside of 236.70%. Given Immuneering's higher probable upside, equities research analysts plainly believe Immuneering is more favorable than Bicycle Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immuneering 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60Bicycle Therapeutics 0 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.70 SummaryImmuneering beats Bicycle Therapeutics on 8 of the 15 factors compared between the two stocks. Get Immuneering News Delivered to You Automatically Sign up to receive the latest news and ratings for IMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMRX vs. The Competition Export to ExcelMetricImmuneeringMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$124.15M$2.90B$5.53B$9.04BDividend YieldN/A2.44%5.24%4.02%P/E Ratio-1.7321.5627.5820.25Price / Sales381.27281.07417.23118.60Price / CashN/A42.7336.8958.07Price / Book2.557.518.035.67Net Income-$61.04M-$55.05M$3.18B$249.21M7 Day Performance-3.97%4.61%2.91%3.28%1 Month Performance65.37%4.72%3.72%5.56%1 Year Performance211.01%5.92%36.04%21.13% Immuneering Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMRXImmuneering4.1024 of 5 stars$3.39-5.6%$13.25+290.9%+200.0%$124.15M$320K-1.7360Positive NewsGap UpBCYCBicycle Therapeutics3.9513 of 5 stars$6.95-4.0%$25.00+259.7%-62.1%$501.40M$25.72M-2.21240News CoverageMNMDMind Medicine (MindMed)3.0973 of 5 stars$6.49-0.9%$25.50+292.9%+0.8%$494.87MN/A-5.0340Positive NewsVALNValneva1.5078 of 5 stars$5.67-2.2%$15.50+173.4%-20.5%$493.55M$183.52M-4.76700ZVRAZevra Therapeutics2.7636 of 5 stars$8.81-2.1%$22.29+153.0%+127.3%$492.12M$23.61M-4.6420News CoverageAnalyst ForecastAnalyst RevisionKURAKura Oncology4.5681 of 5 stars$5.77+1.8%$24.50+324.6%-70.5%$490.88M$53.88M-2.75130TYRATyra Biosciences1.9967 of 5 stars$9.57+5.2%$30.83+222.2%-41.1%$483.12MN/A-5.8720Analyst ForecastBCAXBicara Therapeutics1.4069 of 5 stars$9.29+6.7%$31.86+242.9%N/A$475.01MN/A0.0032ABVXAbivax2.4255 of 5 stars$7.65+3.4%$31.00+305.2%-39.0%$469.56MN/A0.0061News CoveragePositive NewsGap UpHigh Trading VolumeSEPNSepterna1.6905 of 5 stars$10.57+0.6%$26.75+153.1%N/A$468.31M$1.08M0.00N/AORGOOrganogenesis4.0928 of 5 stars$3.66-0.3%$6.00+63.9%+55.9%$465.55M$482.04M-21.53950News Coverage Related Companies and Tools Related Companies BCYC Alternatives MNMD Alternatives VALN Alternatives ZVRA Alternatives KURA Alternatives TYRA Alternatives BCAX Alternatives ABVX Alternatives SEPN Alternatives ORGO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMRX) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuneering Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Immuneering With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMRX Stock Alerts